image credit: Vecteezy

Cortexyme plans path forward for Alzheimer’s drug that failed study

November 12, 2021


Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer’s drug in another study, convinced that signs of benefit observed in some patients are proof its treatment works.

Last month, the company, Cortexyme, reported the drug missed both main goals of a late-stage trial, showing no significant difference versus placebo on tests that measured participants’ cognition and physical function. Yet Cortexyme claimed the negative results had a silver lining, noting that, among a smaller subgroup, the drug appeared to slow cognitive decline by a substantial margin.

Read More on Biopharma Dive